Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Vorinostat in Recurrent Glioblastoma
NCT01738646Phase 2Completed
- Sponsor
- Duke University
- Start
- Jan 2013
- Primary completion
- Dec 2014
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in glioblastoma multiforme (GBM), sponsored by Duke University. Started Jan 2013; status: completed.
02
Drugs
vorinostat
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT01738646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01738646.